Abstract. Capsaicin (8-methyl N-vanillyl-6 nonenamide) is a natural plant extract that has antitumor properties and induces apoptosis and autophagy in various types of malignancies, including hepatocellular carcinoma (HCC). Sorafenib is a multi-kinase inhibitor that improves the survival of patients with advanced HCC. In the present study, capsaicin and sorafenib were found to inhibit the growth of LM3, Hep3B and HuH7 cells. In addition, the combination of capsaicin and sorafenib exerted a synergistic inhibitory effect on HCC cell growth. In LM3 cells, capsaicin and sorafenib combination treatment achieved a markedly stronger induction of apoptosis by increasing caspase-3, Bax and poly(ADP-ribose) polymerase activity and inhibiting Bcl-2, and induction of autophagy by upregulating the levels of beclin-1 and LC3A/B II, enhancing P62 degradation. The combination of capsaicin and sorafenib also inhibited cell invasion and metastasis via upregulation of E-cadherin and downregulation of N-cadherin, vimentin, matrix metalloproteinase (MMP)2 and MMP9. Additional studies suggested an association between the abovementioned anticancer activities and inhibition of the epidermal growth factor receptor/phosphoinositide 3 kinase/Akt/mammalian target of rapamycin pathway. Taken together, these data confirm that capsaicin and sorafenib combination treatment inhibits the growth, invasion and metastasis of HCC cells and induces autophagy in a synergistic manner, supporting its potential as a therapeutic option for HCC.

Introduction

Hepatocellular carcinoma (HCC) is the sixth most prevalent type of cancer and ranks third among the most frequent causes of solid tumor-related deaths worldwide (1). HCC is the most common primary malignancy of the liver, and its incidence has increased in recent decades (2). Patients with advanced unresectable or metastatic HCC often have a poor prognosis, and only a few chemotherapeutics have been proven to be effective (3). Only early-stage HCC patients can receive potentially curative therapies, such as surgical resection and liver transplantation. Therefore, there is an urgent need to identify and develop more effective treatments for HCC (4). Sorafenib, the only systemic therapy that improves the survival of patients with advanced HCC, is a multi-kinase inhibitor (5). The phosphoinositide 3 kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling axis, which plays a pivotal role in cell proliferation, colonization and survival (6), is an emerging target in HCC that contributes to disease progression and the development of resistance to sorafenib. However, sensitivity to sorafenib after the development of resistance may be partially restored by PI3K/Akt inhibitors in vitro (7). Therefore, targeting PI3K/Akt signaling may considerably improve the management of HCC patients treated with sorafenib (8).

Capsaicin (8-methyl N-vanillyl-6 nonenamide) is a natural plant extract and the major pungent component of hot peppers of the genus Capsicum (9). Capsaicin has potential antitumor properties (10) and produces apoptosis in various types of malignancies, including breast cancer (11,12), colon adenocarcinoma (13,14), nasopharyngeal carcinoma (15), esophageal epidermoid carcinoma (16), HCC (17,18) and prostate cancer (19). Capsaicin has been reported to induce apoptosis and autophagy in several types of human carcinoma cells via inhibition of the PI3K/Akt/mTOR signaling pathway (15,18). The activation of PI3K/Akt/mTOR signaling is associated with cancer cell proliferation, colonization and survival. PI3K/Akt/mTOR signaling may inhibit cell apoptosis (20) and autophagy (21), whereas upregulation of this signaling pathway may promote angiogenesis (22), invasion and metastasis (23-25). Therefore, this pathway holds promise as an effective target for the treatment of HCC through the combined use of capsaicin and sorafenib.

Correspondence to: Professor Qiyu Zhang, Department of Surgery, The First Affiliated Hospital of Wenzhou Medical University, Nanbaixiang, Wenzhou, Zhejiang 325015, P.R. China E-mail: qiyuz2016@sina.com

Key words: hepatocellular carcinoma, capsaicin, sorafenib, apoptosis, autophagy, invasion, metastasis, epidermal growth factor receptor/phosphoinositide 3 kinase/Akt/mammalian target of rapamycin signaling
Epidermal growth factor receptor (EGFR) is a growth factor receptor tyrosine kinase, and its isogensic ligands have been found to be commonly affected in multiple cancer types and appear to facilitate solid tumor growth (26). EGFR is located upstream of PI3K/Akt/mTOR and is overexpressed in HCC cells (27). Therefore, the aim of the present study was to investigate the antitumor activity of capsaicin and sorafenib in \textit{in vitro} and \textit{in vivo} studies, alone as well as in combination, in order to determine whether their combination can induce HCC cell apoptosis and autophagy and inhibit HCC cell proliferation, migration and invasion in a synergistic manner.

Materials and methods

**Chemicals and antibodies.** Capsaicin and sorafenib were purchased from Sigma-Aldrich; Merck KGaA (St. Louis, MO, USA) and Selleckchem (Houston, TX, USA), respectively. Antibodies against GAPDH, Bax, cleaved caspase-3 (Asp175), poly(ADP-ribose) polymerase (PARP), beclin-1, LC3A/B, E-cadherin, vimentin, P-Akt (Ser473), Akt, P-mTOR (Ser2448), mTOR, P-p70S6 kinase (P-p70S6K, Thr389), p70S6K and Ki-67 were obtained from Cell Signaling Technology (Danvers, MA, USA). The P62 antibody was obtained from Proteintech (Rosemont, IL, USA). The antibodies against Bcl-2, N-cadherin, matrix metalloproteinase (MMP)2, MMP9, P-EGFR, EGFR and PI3K p85α were obtained from Abcam (Cambridge, MA, USA). The details on the antibodies used in the present study are listed in Table I.

**Cell lines and culture conditions.** The LM3, Hep3B and HuH7 human HCC cell lines were obtained from the Cell Bank of Type Culture Collection of Chinese Academy of Sciences (Shanghai, China). The cells were maintained in Dulbecco's modified Eagle's medium (DMEM; Gibco; Thermo Fisher Scientific Inc., Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific Inc.) at 37°C in a humidified atmosphere (5% CO₂, 95% air). The HCC LM3 cell line used in this study has been authenticated by STR profiling.

**Cell viability and colony formation assays.** To allow cells to attach completely, LM3, Hep3B and HuH7 cells (5,000 cells/well) were seeded in a 96-well plate for 24 h; then, capsaicin and sorafenib were added to the culture media at the indicated concentrations for another 48 h. Next, 10% Cell Counting Kit (CCK)-8 solution was added to the culture media, and the plates were incubated for 4 h. OD450 values were determined by a spectrophotometer, and the results were analyzed to measure cell growth.

For colony formation assays, adherent cells were trypsinized, and 1,000 viable cells were re-seeded in 6-well plates (in triplicate). After cell adherence, cells were allowed to form colonies for 14 days with each of the treatments. To visualize the colonies, the media were discarded, and the cells were submerged in 4% paraformaldehyde for 15 min and dyed with 0.1% crystal violet staining solution.

**Cell migration and invasion assays.** LM3 cells were seeded and cultured in a 6-well plate for 24 h to adherence and confluenct. The cell layers were scratched with a 200-μl pipette tip to create a wound and then washed three times with phosphate-buffered saline (PBS) to remove floating cells. The medium was then replaced with serum-free medium. The wound was photographed at 0, 48 and 72 h.

After trypsinization, 2x10^5 cells were plated on Boyden chambers coated with 10 μg Matrigel (BD Biosciences, Sparks, MD, USA) per well (for invasion assays), and 5x10^4 cells were plated on uncoated Boyden chambers (for migration assays) in medium containing 1% FBS. Medium containing 10% FBS was added to the lower chamber as a chemoattractant. Capsaicin, sorafenib or their combination was added to the upper and lower chambers at the indicated concentrations. After 48 h, the cells that had moved to the lower surface of the membrane were fixed with methanol and stained with 0.1% crystal violet solution. Photographs of three random fields of fixed cells were captured, and the cells were counted. Each reported value was estimated from three plates.

**Immunofluorescence.** Cells (2x10^5) were cultured on sterile sheet glass and treated with capsaicin, sorafenib or their combination for 48 h. The cells were submerged in 4% paraformaldehyde solution at room temperature for 10 min after treatment, then washed three times in PBS, permeabilized with 0.1% Triton X-100/PBS for 5 min, and then blocked with 10% bovine serum albumin for 1 h. The cells were incubated with primary antibodies overnight at 4°C, washed three times in PBS for 15 min, and incubated with secondary antibodies for 1 h at room temperature. Unbound Ab was removed by washing with 1X TBST four times for 20 min each time; thereafter, the cell nuclei were stained with DAPI (1:20). ProLong® Gold Antifade Mounting Agent (Thermo Fisher Scientific, Inc.) was used for treating the cells, and fluorescence images were captured by a fluorescence microscope.

**Western blotting.** Following treatment with capsaicin, sorafenib or their combination, cells were lysed in radio-immunoprecipitation assay buffer (Beyotime Institute of Biotechnology, Shanghai, China) containing 1% phenylmethysulfonyl fluoride (Beyotime Institute of Biotechnology) and 10% phosphatase inhibitor (Roche Diagnostics GmbH, Mannheim, Germany) per well (for invasion assays), and 5x10^4 cells were plated on uncoated Boyden chambers (for migration assays) in medium containing 1% FBS. Medium containing 10% FBS was added to the lower chamber as a chemoattractant. Capsaicin, sorafenib or their combination was added to the upper and lower chambers at the indicated concentrations. After 48 h, the cells that had moved to the lower surface of the membrane were fixed with methanol and stained with 0.1% crystal violet solution. Photographs of three random fields of fixed cells were captured, and the cells were counted. Each reported value was estimated from three plates.

**Apoptosis analysis with flow cytometry and TdT-mediated dUTP nick end labeling (TUNEL).** For the apoptosis analysis, LM3 cells were treated with capsaicin, sorafenib
or their combination for the indicated times, trypsinized and collected in tubes, and incubated in binding buffer with propidium iodide and FITC-conjugated Annexin V for 10 min in the dark at room temperature. Flow cytometry analysis was used to estimate the cell apoptosis rate. The TUNEL method was applied to visualize the 3'-OH ends of DNA fragments in apoptotic cells according to the manufacturer's protocol (Roche Diagnostics GmbH). LM3 cells were subjected to different treatments for 48 h and fixed in 4% paraformaldehyde. The cells were then submerged in methanol containing 0.3% H2O2 to inhibit endogenous peroxidase activity. Following washing with PBS, cells were covered with proteinase K solution for 10 min. Subsequently, the cells were covered with the TUNEL reaction mixture and incubated for 1 h at 37˚C in the dark. After washing in PBS, the cells were placed in Converter-POD (Roche Diagnostics GmbH) and then incubated at 37˚C for 30 min. After rinsing in PBS three times for 5 min, the cells were dipped in DAB (Roche Diagnostics GmbH) at room temperature for 10 min and observed under a microscope.

In vivo studies. Five-week-old BALB/C nude mice (SPF grade) were supplied by SLAC Co., Ltd. (Shanghai, China). All the mice were raised in the cabinet with laminar air flow under pathogen-free conditions in a humidity- and temperature-controlled environment with a 12 h light/dark schedule. The mice had *ad libitum* access to food and water. Prior to the study initiation, the mice were allowed to acclimate for 1 week. Then, the mice received a subcutaneous injection of 1x10^7 LM3 cells suspended in 100 µl sterile PBS into the right flank. Two weeks after the inoculation, based on the initial tumor volume, the mice were divided into four groups (n=6 per group) and received daily treatments via i.p. injections: The control group received sterile PBS with 1% dimethyl sulfoxide (DMSO), the capsaicin group was treated with 5 mg/kg capsaicin containing 1% DMSO, the sorafenib group received 50 mg/kg sorafenib containing 1% DMSO, and the combination group was treated with 5 mg/kg capsaicin + 50 mg/kg sorafenib containing 1% DMSO. Tumor volume and mouse weight were measured every other day, and tumor volume was calculated according to the formula V (mm^3) = 1/2 (length x width^2). The mice were treated with different compounds for 28 days. All the mice were sacrificed by cervical dislocation under pentobarbital sodium anesthesia administered through i.p. injection, the livers and kidneys were harvested for immunohistochemical examination and blood was collected for biochemistry tests. All efforts were made to minimize animal suffering. All animal procedures were conducted in accordance with the guidelines of the National Institutes of Health and were approved by the Ethical Committee of Wenzhou Medical University and the Laboratory Animal

| Antibody Description                  | Dilution | Catalogue no.   | Company details          |
|---------------------------------------|----------|-----------------|--------------------------|
| GAPDH                                 | WB 1:1,000 | 5174            | Cell Signaling Technology^a |
| Bax                                   | WB 1:1,000, IHC 1:200 | 5023        | Cell Signaling Technology^a |
| Cleaved caspase-3 (Asp175)            | WB 1:1,000 | 9664            | Cell Signaling Technology^a |
| PARP antibody                         | WB 1:1,000 | 9542            | Cell Signaling Technology^a |
| Beclin-1                              | WB 1:1,000 | 3495            | Cell Signaling Technology^a |
| LC3A/B antibody                       | WB 1:1,000 | 4108            | Cell Signaling Technology^a |
| E-cadherin                            | WB 1:1,000 | 3195            | Cell Signaling Technology^a |
| Vimentin                              | WB 1:1,000 | 5741            | Cell Signaling Technology^a |
| Phospho-Akt (Ser473)                  | WB 1:1,000, IHC 1:200 | 4060        | Cell Signaling Technology^a |
| Akt (pan)                             | WB 1:1,000 | 4691            | Cell Signaling Technology^a |
| Phospho-mTOR (Ser2448)                | WB 1:1,000 | 5536            | Cell Signaling Technology^a |
| mTOR                                  | WB 1:1,000 | 2983            | Cell Signaling Technology^a |
| Phospho-p70 S6 kinase (Thr389)        | WB 1:1,000 | 9234            | Cell Signaling Technology^a |
| p70 S6 kinase                         | WB 1:1,000 | 2708            | Cell Signaling Technology^a |
| Ki-67                                  | IHC 1:200 | 12202           | Cell Signaling Technology^a |
| P62/SQSTM1 antibody                   | WB 1:1,000, IHC 1:200 | 18420-1-AP | Proteintech^b |
| Anti-N-cadherin antibody               | WB 1:1,000 | ab18203         | Abcam^c |
| Anti-MMP2 antibody                    | WB 1:1,000, IHC 1:200 | ab37150    | Abcam^c |
| Anti-PI 3 kinase p85 alpha antibody    | WB 1:1,000 | ab86714         | Abcam^c |
| Anti-EGFR antibody                    | WB 1:1,000, IHC 1:200 | ab52894    | Abcam^c |
| Anti-MMP9 antibody                    | WB 1:1,000, IHC 1:200 | ab38898    | Abcam^c |
| Anti-Bcl-2 antibody                   | WB 1:1,000 | ab32124         | Abcam^c |
| Anti-EGFR (phospho Y1068) antibody    | WB 1:1,000, IHC 1:200 | ab40815    | Abcam^c |

Species: Human. ^aDanvers, MA, USA. ^bRosemont, IL 60018, USA. ^cCambridge, UK. WB, western blotting; IHC, immunohistochemistry.
Figure 2. Capsaicin, sorafenib and the IR combination inhibit colony formation in LM3 cells. In the colony formation assay, the formed colonies were counted manually for each group of cells and are presented as the means ± standard error of the mean from three separate experiments. ***P<0.005. Con, control; Cap, capsaicin 80 µM; Sora, sorafenib 4 µM.

Figure 1. Inhibitory effect of capsaicin, sorafenib and their combined treatment on tumor cell viability. (A-C) Capsaicin dose-dependently reduced the viability of the hepatocellular carcinoma (HCC) cells Hep3b, Huh7 and LM3. (D-F) Sorafenib dose-dependently reduced the viability of the HCC cells Hep3b, Huh7 and LM3. Cells were incubated with different concentrations of capsaicin and sorafenib for 48 h before being subjected to a Cell Counting Kit (CCK)-8 assay. (G-I) Effect of capsaicin and sorafenib combination treatment compared with the single-drug treatment on cell viability in Hep3b, Huh7 and LM3 cell lines. Cells were incubated with capsaicin, sorafenib and their combination for 48 h before being subjected to an CCK-8 assay. The data are presented as the mean ± standard error of the mean. **P<0.01, ***P<0.005.
Management Committee of Zhejiang Province (Approval ID: wydw2017-0052).

**Immunohistochemistry.** The tumors were fixed with 4% paraformaldehyde solution and embedded in paraffin, then cut into 4-µm sections. The slides were incubated with antibodies against P-EGFR, P-Akt, Ki67, Bax, P62, MMP2 and MMP9; then, the slides were washed, stained with secondary antibody, and directly visualized by the ChemMate EnVision Kit (ZSGB-BIO Beijing China). Images of the stained sections were captured under a microscope at a magnification of x400. Histological analysis of liver and kidney sections was conducted with hematoxylin and eosin (H&E) staining. Details on the antibodies used may be found in Table I.

**Statistical analysis.** The data are presented as the mean ± standard error of the mean for given samples, and were analyzed by one-way analysis of variance (ANOVA) followed by Dunnett’s multiple range tests using SPSS v.22 statistical software (IBM Corp., Armonk, NY, USA). The significance level was set at P<0.05.

**Results**

**Capsaicin reduces cell viability and potentiates the inhibitory effects of sorafenib in HCC lines.** CCK-8 assays were performed to evaluate the effects of capsaicin and sorafenib alone and in combination on three human HCC cell lines, LM3, Hep3B and HuH7 (Fig. 1A-I). The survival and proliferation of these four cell lines decreased with increasing concentrations of capsaicin and sorafenib. The inhibition of cell survival and proliferation was greatly enhanced by the combination of a low concentration of capsaicin and a moderate concentration of sorafenib.

**Different combinations of capsaicin and sorafenib inhibit LM3 cell proliferation to various extents.** In colony formation assays, LM3 cells treated with the combination of capsaicin and sorafenib exhibited decreased colony formation ability compared with those treated with monotherapy (Fig. 2). The effects of capsaicin in combination with sorafenib on LM3 cells are further detailed in Table II. In LM3 cells, the IC50 of sorafenib in combination with capsaicin (80, 100 and 120 µM) was significantly decreased from 3.987 µM to 2.989, 2.590 and 1.854 µM, respectively, and significant synergy between sorafenib and capsaicin was observed at 80, 100 and 120 µM capsaicin.

**Capsaicin acts synergistically with sorafenib to induce apoptosis in the LM3 cell line.** Based on the results in Table II, the combination of 80 µM capsaicin and 4 µM sorafenib was selected for the next series of experiments. To ascertain the extent of apoptosis, cells were examined by TUNEL staining. Following treatment with capsaicin and sorafenib, microscopic examination revealed stained cells, and the combination of capsaicin and sorafenib was associated with a higher number of TUNEL-positive cells (Fig. 3A). To further validate apoptotic cell death induced by capsaicin and sorafenib alone and in combination, apoptosis was evaluated by flow cytometry analysis. The combination treatment triggered apoptosis to a greater extent than either monotherapy. As shown in Fig. 3B, the percentage of apoptotic cells after 48 h of treatment with...
Figure 3. Capsaicin and sorafenib induce apoptosis in LM3 cells, and their combination exerts a synergetic effect on cell apoptosis. (A) TUNEL staining was used to visualize the 3'-OH ends of DNA fragments in apoptotic cells. Representative photomicrographs of cells under control or drug treatments are shown (magnification, x100). (B) LM3 cells were treated with capsaicin, sorafenib and their combination for 48 h and were then stained with Annexin V and propidium iodide (PI). The early apoptotic cells (Annexin V-positive, PI-negative) and the late apoptotic cells (Annexin V-positive, PI-positive) are indicated as the percentage of gated cells. The histogram represents the apoptotic cells for each dose. Data are presented as the mean ± standard error of the mean (SEM) of three experiments. (C) Western blot analysis of Bax, Bcl-2, cleaved caspase-3 and cleaved PARP after capsaicin, sorafenib and combination treatment for 12 h. The results are representative of three separate experiments. GAPDH was set as control. The data are presented as the mean ± SEM. ***P<0.005; #, Capsaicin vs. combination; +, sorafenib vs. combination. ###/+++: P<0.005. Con, control; Cap, capsaicin 80 µM; Sora, sorafenib 4 µM; PI, propidium iodide; PARP, poly(ADP-ribose) polymerase.
control, 80 µM capsaicin, 4 µM sorafenib and the combination of 80 µM capsaicin and 4 µM sorafenib was 3.43±0.536, 16.58±0.629, 21.18±0.809 and 52.13±1.602%, respectively. To further elucidate the mechanism underlying the increased apoptosis of LM3 cells, the protein levels of two key apoptosis-related protein, Bcl2 and Bax, were investigated. The pro-apoptotic protein Bax expression was upregulated by the capsaicin and sorafenib combination, and the expression of the anti-apoptotic protein Bcl2 was reduced (Fig. 3C). Caspase-3 was also examined by western blot assays. As shown, exposure to 80 µM capsaicin and 4 µM sorafenib for 24 h increased the cleavage of caspase-3. The results mentioned above indicate that capsaicin combined with sorafenib can modulate the activation of apoptotic signaling pathways in LM3 cells.

Capsaicin combined with sorafenib enhances autophagy in the LM3 cell line. To determine the effect of the capsaicin and sorafenib combination treatment on cell autophagy, the protein expression of the autophagy-related genes beclin-1, P62 and LC3A/B-II was examined by western blotting (Fig. 4). Beclin-1 and LC3A/B-II levels were increased by the combination treatment compared with monotherapy. Compared with the monotherapy groups, the autophagy-specific substrate P62 was obviously reduced in the combination group.

The capsaicin and sorafenib combination markedly inhibits LM3 cell invasion and migration. Cell scratch assays were used to determine whether capsaicin and sorafenib inhibit HCC cell migration. As shown in Fig. 5A, the LM3 cell-free area...
after the combination treatment was wider compared with that after monotherapy, and the wound was wider in the treatment groups compared with that in the control group at 48 and 72 h. This result demonstrated that capsaicin and sorafenib inhibit LM3 cell migration in a synergistic manner. Transwell migration assays and Matrigel invasion assays (Fig. 5B) revealed that capsaicin and sorafenib can inhibit both the migration and invasion of LM3 cells, and the combined treatment was
more effective than either monotherapy. Therefore, we next examined the expression levels of E-cadherin, N-cadherin, vimentin, MMP2 and MMP9 in the monotherapy and combination groups through western blotting. The N-cadherin, vimentin, MMP2 and MMP9 levels were markedly decreased in LM3 cells after treatment with the combination of capsaicin and sorafenib, while the E-cadherin levels were increased (Fig. 5C).

Capsaicin combined with sorafenib obviously inhibits the expression of EGFR and downstream effectors of the EGFR/PI3K/Akt/mTOR signaling pathway in LM3 cells. To elucidate the mechanism underlying the synergistic effects of capsaicin and sorafenib, we investigated PI3K/Akt/mTOR signal transduction, which is critically implicated in the effects of capsaicin and sorafenib. Capsaicin and sorafenib treatment decreased the levels of PI3K, P-Akt, P-mTOR and P-p70S6K, and these levels were lower in LM3 cells after combination treatment compared with after either monotherapy (Fig. 6). PI3K/Akt/mTOR signaling may be activated by multiple stimuli. Growth factor receptor family proteins are major upstream molecules of PI3K/Akt/mTOR signaling (28). A number of solid tumors display high or abnormal EGFR expression. EGFR is associated with tumor cell proliferation, angiogenesis, invasion, metastasis and inhibition of apoptosis (29). Therefore, P-EGFR and EGFR levels were examined in LM3 cells following treatment with capsaicin, sorafenib, or their combination. The P-EGFR and EGFR levels decreased in LM3 cells treated with capsaicin and sorafenib, and the combination treatment synergistically downregulated P-EGFR and EGFR levels, which were lower compared with those in the monotherapy groups. Therefore, it was concluded that EGFR and PI3K/Akt/mTOR signaling was inhibited synergistically by capsaicin and sorafenib.

Capsaicin and sorafenib restrain the growth of hepatocellular tumors synergistically in vivo. To further confirm capsaicin and sorafenib as synergistic inhibitors of tumor growth in vivo, 1x10^7 LM3 cells were subcutaneously inoculated in nude mice. Capsaicin and sorafenib treatment was administered i.p. for 28 days starting at the 7th day post-inoculation. It was observed that the capsaicin and sorafenib combination treatment exerted an obvious inhibitory effect on tumor volume (Fig. 7A and B). However, there were no significant differences
in body weight between the control and treatment groups (Fig. 7A). Furthermore, the expression levels of proteins related to proliferation, apoptosis, autophagy, invasion and metastasis in xenograft tumor tissues were evaluated by immunohistochemistry. Proliferation, invasion and metastasis were inhibited in xenograft tumors by capsaicin, sorafenib and their combination, while apoptosis and autophagy were activated (Fig. 7C). Ki67 and Bax indicated the presence of more apoptotic cells and obviously fewer proliferative cells in tumors treated with the combination of capsaicin and sorafenib. In addition, the highest autophagy level among the four groups, as measured by P62, was observed in tumors of the combination treatment group. Capsaicin and sorafenib decreased MMP2 and MMP9 expression in the tumors, and the combination treatment enhanced this effect. Moreover, P-EGFR and P-Akt levels were evaluated in xenograft tumors and it was observed that the capsaicin and sorafenib combination decreased P-EGFR and P-Akt levels to the greatest extent. The biochemical function of the liver and kidney was monitored, and there were no significant differences among the four groups (Fig. 7D). To further evaluate treatment-related toxicity, liver and kidneys from the control and drug-treated groups were stained with H&E. The histological structure of the liver and kidneys was compared under the microscope, and no considerable histological changes were observed following treatment with capsaicin, sorafenib, or their combination (Fig. 7E). These results suggest that capsaicin and sorafenib combination treatment can effectively inhibit the growth, invasion and metastasis of xenograft hepatocellular tumors in vivo in a synergistic manner, with well-tolerated toxicity.

Discussion

The multi-kinase inhibitor sorafenib is the only systemic therapy that improves the survival of patients with advanced HCC, but its efficacy is not satisfactory. The aim of the present study was to ascertain the synergistic effect of capsaicin and sorafenib against HCC. It was observed that capsaicin and sorafenib exerted synergistic antitumor effects on HCC cells in vitro as well as in vivo. Capsaicin induces apoptosis and autophagy through the PI3K/Akt/mTOR pathway (15) and suppresses EGF-induced invasion and metastasis of tumor cells (30). Sorafenib inhibits HCC growth by decreasing the expression of PI3K/Akt/mTOR pathway components (31). In addition, inhibition of the PI3K/Akt/mTOR pathway enhances sorafenib-induced autophagy in HCC cells (32,33). EGFR is overexpressed in HCC cells (27). Overexpression or mutation of EGFR leads to activation of the PI3K/Akt/mTOR pathway. In addition, activated Akt affects a variety of biological processes via phosphorylation cascades involving numerous
proteins; Akt activation promotes tumor cell growth, proliferation, invasion and metastasis, regulates tumor angiogenesis and inhibits apoptosis (29).

In the present study, four HCC cell lines were examined to observe the effects of capsaicin, sorafenib and their combination on cell proliferation. Capsaicin inhibited the growth of three HCC cell lines at 48 h, with IC_{50} values between 44.7 \mu M (HuH7) and 95.7 \mu M (LM3). Sorafenib inhibited HCC cell growth at 48 h, with IC_{50} values between 0.99 \mu M (HuH7) and 4.02 \mu M (LM3). Then, HCC cells were treated with a low concentration of capsaicin and a moderate concentration of sorafenib, and synergistic inhibitory effects were observed.

The LM3 cell line was selected for subsequent studies, as it has a strong capacity for growth and is sensitive to both capsaicin and sorafenib. The 80 \mu M capsaicin and 4 \mu M sorafenib combination was selected for further studies after analyzing various combinations of capsaicin and sorafenib in LM3 cells.

We investigated apoptosis, autophagy, invasion and metastasis in LM3 cells treated with capsaicin and/or sorafenib, and it was concluded that capsaicin and sorafenib inhibit proliferation, invasion and metastasis and induce apoptosis and autophagy in LM3 cells in a synergistic manner. Therefore, the expression of EGFR/PI3K/Akt/mTOR signaling components was further examined in LM3 cells. The results demonstrated that capsaicin

---

**Figure 7. Continued.** Capsaicin and sorafenib inhibit HCC cancer cell growth, invasion and metastasis synergistically *in vivo*. (C) The apoptosis, autophagy, invasion, metastasis and phosphorylation of Ki67, Bax, P62, matrix metalloproteinase (MMP)2, MMP9, P-Akt and P-EGFR in xenograft tumor tissues were detected by immunohistochemistry (magnification, x400). Con, control; Cap, capsaicin; Sora, sorafenib.

|   | Con | Cap | Sora | Cap + Sora |
|---|-----|-----|------|------------|
| Ki67 | ![Image](image1) | ![Image](image2) | ![Image](image3) | ![Image](image4) |
| Bax | ![Image](image5) | ![Image](image6) | ![Image](image7) | ![Image](image8) |
| P62 | ![Image](image9) | ![Image](image10) | ![Image](image11) | ![Image](image12) |
| MMP2 | ![Image](image13) | ![Image](image14) | ![Image](image15) | ![Image](image16) |
| MMP9 | ![Image](image17) | ![Image](image18) | ![Image](image19) | ![Image](image20) |
| P-EGFR | ![Image](image21) | ![Image](image22) | ![Image](image23) | ![Image](image24) |
| P-Akt | ![Image](image25) | ![Image](image26) | ![Image](image27) | ![Image](image28) |
and sorafenib inhibited EGFR/PI3K/Akt/mTOR signaling and that their combination exerted a synergistic inhibitory effect on EGFR/PI3K/Akt/mTOR signaling in LM3 cells.

Compared with monotherapy, the capsaicin and sorafenib combination treatment induced apoptosis and autophagy synergistically, as evidenced by western blotting, TUNEL staining and immunofluorescence staining. Apoptosis and autophagy play key roles in cancer progression. Moreover, the same synergistic effect on invasion and metastasis was observed. Cell scratch, Transwell migration, Matrigel invasion and immunofluorescence assays all demonstrated that capsaicin and sorafenib inhibited LM3 cell invasion and metastasis in a synergistic manner. Activation of PI3K/Akt/mTOR signaling increases tumor cell apoptosis, invasion and metastasis; therefore, inhibiting PI3K/Akt/mTOR signaling can inhibit tumor cell apoptosis, invasion and metastasis (34,35). Additionally, it has been demonstrated by previous studies that mTOR (particularly mTORC1) plays an important role in regulating autophagy, with PI3K/Akt signaling as the key upstream effector (36,37). In addition, it was reported that autophagy in HCC cells can be induced by inhibiting the PI3K/Akt/mTOR pathway (38,39). The present study demonstrated that the capsaicin and sorafenib combination decreased the expression levels of P-Akt, PI3K, P-mTOR and P-p70S6K and exerted a synergistic inhibitory effect on PI3K/Akt/mTOR signaling in LM3 cells. It is likely that capsaicin and sorafenib combination treatment inhibits LM3 cell proliferation, invasion and metastasis and enhances apoptosis and autophagy.

Figure 7. Continued. Capsaicin and sorafenib inhibit HCC cancer cell growth, invasion and metastasis synergistically in vivo. (D) The liver and kidney biochemical functions were evaluated. The AST, ALT, BUN, CR and BUN/CR levels of were detected in mouse blood by ELISA. (E) The liver and kidneys from the control and the three treatment groups were stained with hematoxylin and eosin to evaluate the toxicity after treatment. The histological structures of the liver and kidney were observed and compared microscopically (magnification, x200). AST, aspartate aminotransferase; ALT, alanine aminotransferase; BUN, blood urea nitrogen; CR, creatinine; Con, control; Cap, capsaicin; Sora, sorafenib.
synergistically through the PI3K/Akt/mTOR pathway. The in vivo experiments yielded the same results: The combination treatment exerted synergistic effects on tumor proliferation, invasion and metastasis. P-EGFR and EGFR levels were next measured in LM3 cells and found that treatment with capsaicin or sorafenib alone decreases P-EGFR and EGFR levels, whereas the combination treatment exerts a synergistic effect. The combination treatment also decreased P-EGFR and P-Akt levels in a synergistic manner in mouse xenograft tumors.

In conclusion, a strong growth inhibitory effect of capsaicin and sorafenib combination was observed in LM3 cells by decreasing EGFR levels and PI3K/Akt/mTOR downstream signaling. Capsaicin acted synergistically with sorafenib to inhibit LM3 cell growth, invasion and metastasis and to enhance apoptosis and autophagy in vitro as well as in vivo. The combination treatment is associated with the inhibition of EGFR and PI3K/Akt/mTOR signaling, with concomitant increases in cleaved caspase-3, Bax, cleaved PARP, beclin-1, LC3A/B-II and E-cadherin, and decreases in Bcl-2, P62, N-cadherin, MMP2, MMP9 and vimentin. Therefore, this combination may be a promising approach to the treatment of patients with advanced HCC.

Acknowledgements

Not applicable.

Funding

The present study was supported by the National Natural Science Funding of China (grant no. 81470874), the Zhejiang Provincial Natural Science Foundation of China (grant no. LY13H030009).

Availability of data and materials

All data generated/analyzed in the present study are available from the corresponding author on reasonable request.

Authors’ contributions

QH contributed to the conception of the study; PG contributed significantly to the analysis and manuscript preparation; ND and RY performed the data analyses and wrote the manuscript; HC helped perform the analysis with constructive discussions; QZ was involved in the conception of the study and approved the final version of the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

All animal procedures were conducted in accordance with the guidelines of the National Institutes of Health and were approved by the Ethical Committee of Wenzhou Medical University and the Laboratory Animal Management Committee of Zhejiang Province (Approval ID: wydw2017-0052).

Patient consent for publication

Not applicable.

Competing interests

All the authors declare that they have no competing interests to disclose.

References

1. Laursen L: A preventable cancer. Nature 516 (Suppl): S2-S3, 2014.
2. Gomaa AI, Khan SA, Toledano MB, Waked I and Taylor-Robinson SD: Hepatocellular carcinoma: Epidemiology, risk factors and pathogenesis. World J Gastroenterol 14: 4300-4308, 2008.
3. Xie B, Wang DH and Spechler SJ: Sorafenib for treatment of hepatocellular carcinoma: A systematic review. Dig Dis Sci 57: 1122-1129, 2012.
4. Colombo M and Sangiovanni A: Treatment of hepatocellular carcinoma: Beyond international guidelines. Liver Int 35 (Suppl 1): S129-S138, 2015.
5. Llovet JM and Hernandez-Gea V: Hepatocellular carcinoma: Reasons for phase III failure and novel perspectives on trial design. Clin Cancer Res 20: 2072-2079, 2014.
6. Osaki M, Oshimura M and Ito H: PI3K-Akt pathway: Its functions and alterations in human cancer. Apoptosis 9: 667-676, 2004.
7. Wang H and Chen L: Tumor microenviroment and hepatocellular carcinoma metastasis. J Gastroenterol Hepatol 28 (Suppl 1): S43-S48, 2013.
8. Gao JJ, Shi ZY, Xia JF, Inagaki Y and Tang W: Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma. World J Gastroenterol 21: 12059-12070, 2015.
9. Sricharoen P, Lamaiphan N, Patthawaro P, Limchoowong N, Techawongstien S and Chanthai S: Phytochemicals in Capsicum oleoresin from different varieties of hot chilli peppers with their antiinflammatory and antioxidant activities due to some phenolic compounds. Ultrasan Sonochem 38: 629-639, 2017.
10. Diaz-Laviada I and Rodriguez-Henche N: The potential anti-tumor effects of capsaicin. Prog Drug Res Fortschritte der Arzneimittelforschung Progres Des Recherches Pharm 68: 181-208, 2014.
11. Naziroglu M, Ciğ B, Blum W, Vizlser C, Buhala A, Marton A, Katona R, Jösvay K, Schwaller B, Oláh Z and Peczé L: Targeting breast cancer cells by MRS1477, a positive allosteric modulator of TRPV1 channels. PLoS One 12: e0179950, 2017.
12. Lee JY, Lee SY, Kim GG, Har MG, Yang SD, Park JH and Kim SW: Development of 68-Ga-SCN-DOTA-Capsaicin as an imaging agent targeting apoptosis and cell cycle arrest in breast cancer. Cancer Biother Radiopharm 32: 169-175, 2017.
13. Yoshitani SI, Tanaka T, Kohno H and Takashima S: Chemoprevention of azoxymethane-induced rat colon carcinogenesis by dietary capsaicin and rotenone. Int J Oncol 19: 929-939, 2001.
14. Kim YM, Hwang JT, Kwak DW, Lee YK and Park OJ: Involvement of AMPK signaling cascade in capsaicin-induced apoptosis of HT-29 colon cancer cells. Ann N Y Acad Sci 1095: 496-503, 2007.
15. Lin YT, Wang HC, Hsu YC, Cho CL, Yang MY and Chien CY: Capsaicin induces autophagy and apoptosis in human nasopharyngeal carcinoma cells by downregulating the PI3K/AKT/mTOR pathway. Int J Mol Sci 18: E1343, 2017.
16. Wu CC, Lin JP, Yang IS, Chou ST, Chen SC, Lin YT, Lin HL and Chung JG: Capsaicin induced cell cycle arrest and apoptosis in human esophagus epidermoid carcinoma CE 81T/VGH cells through the elevation of intracellular reactive oxygen species and Ca2+ productions and caspase-3 activation. Mutat Res 601: 71-82, 2006.
17. Huang SP, Chen JC, Wu CC, Chen CT, Tang NY, Ho YT, Lo C, Lin JP, Chung JG and Lin JG: Capsaicin-induced apoptosis in human hepatoma HepG2 cells. Anticancer Res 29: 165-174, 2009.
18. Chen X, Tan M, Xie Z, Feng B, Zhao Z, Yang K, Hu C, Liao N, Wang T, Chen D, et al: Inhibiting ROS-STAS3-dependent autophagy enhanced capsaicin-induced apoptosis in human hepatocellular carcinoma cells. Free Radic Res 50: 744-755, 2016.
19. Lee JH, Kim C, Baek SH, Ko JH, Lee SG, Yang WM, Um JY, Sethi G and Ahn KS: Capsazepine inhibits JAK/STAT3 signaling, tumor growth, and cell survival in prostate cancer. Oncotarget 8: 17700-17711, 2017.
20. Xin M and Deng X: Nicotine inactivation of the proapoptotic function of Bax through phosphorylation. J Biol Chem 280: 10781-10789, 2005.
21. Yu X, Long YC and Shen HM: Differential regulatory functions of three classes of phosphatidylinositol and phosphoinositide 3-kinases in autophagy. Autophagy 11: 1711-1728, 2015.
22. Choudhari SK, Chaudhary M, Bagde S, Gadabai AR and Joshi V: Nitric oxide and cancer: A review. World J Surg Oncol 11: 118, 2013.
23. Qian Y, Corum L, Meng Q, Blenis J, Zheng JZ, Shi X, Flynn DC and Jiang BH: PI3K induced actin filament remodeling through Akt and p70S6K1: Implication of essential role in cell migration. Am J Physiol Cell Physiol 286: C153-C163, 2004.
24. Kim D, Kim S, Koh H, Yoon SO, Chung AS, Cho KS and Chung J: Akt/PKB promotes cancer cell invasion via increased motility and metalloproteinase production. FASEB J 15: 1953-1962, 2001.
25. Grille SJ, Bellacosa A, Upson J, Klein-Szanto AJ, van Roy F, Lee-Kwon W, Donowitz M, Tsichlis PN and Larue L: The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines. Cancer Res 63: 2172-2178, 2003.
26. Nicholson RJ, Gee JM and Harper ME: EGFR and cancer prognosis. Eur J Cancer 37 (Suppl 4): S9-S15, 2001.
27. Kannangai R, Sahin F and Torbenson MS: EGFR is phosphorylated at Ty845 in hepatocellular carcinoma. Mod Pathol 19: 1456-1461, 2006.
28. O'Reilly KE, Rojo F, She QW, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL., et al: mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66: 1500-1508, 2006.
29. Cheng GZ, Park S, Shu S, He L, Kong W, Zhang W, Yuan Z, Wang LH and Cheng QJ: Advances of AKT pathway in human oncogenesis and as a target for anti-cancer drug discovery. Curr Cancer Drug Targets 8: 2-6, 2008.
30. Hwang YP, Yun HJ, Choi JH, Han EH, Kim HG, Song GY, Kwon KI, Jeong TC and Jeong HG: Suppression of EGFR-induced tumor cell migration and matrix metalloproteinase-9 expression by capsaicin via the inhibition of EGFR-mediated FAK/Akt, PKC/Raf/ERK, p38 MAPK, and AP-1 signaling. Mol Nutr Food Res 55: 594-605, 2011.
31. Zhang CZ, Wang XD, Wang HW, Cai Y and Chao LQ: Sorafenib inhibits liver cancer growth by decreasing mTOR, AKT, and PI3K expression. J BUON 20: 218-222, 2015.
32. Cui SX, Shi WN, Song ZY, Wang SQ, Yu XF, Gao ZH and Qu XJ: Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways. Oncotarget 7: 36767-36782, 2016.
33. Jiang S, Wang Q, Feng M, Li J, Guan Z, An D, Dong M, Peng Y, Kuerban K and Ye L: C2-ceramide enhances sorafenib-induced caspase-dependent apoptosis via PI3K/AKT/mTOR and Erk signaling pathways in HCC cells. Appl Microbiol Biotechnol 101: 1533-1546, 2017.
34. Lee DH, Szczepanski MJ and Lee YJ: Magnolol induces apoptosis via inhibiting the EGFR/PI3K/Akt signaling pathway in human prostate cancer cells. J Cell Biochem 106: 1113-1122, 2009.
35. Zhang L, Wang F, Jiang Y, Xu S, Lu F, Wang W, Sun X and Sun X: Migration of retinal pigment epithelial cells is EGFR/PI3K/AKT dependent. Front Biosci (Schol Ed) 5: 661-671, 2013.
36. He C and Klionsky DJ: Regulation mechanisms and signaling pathways of autophagy. Ann Rev Genet 43: 67-93, 2009.
37. Jacinto E, Facchinetti V, Liu D, Soto N, Wei S, Jung SY, Huang Q, Qin J and Su B: SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 127: 125-137, 2006.
38. Li TT, Zhu D, Mou T, Guo Z, Pu JL, Chen QS, Wei XF and Wu ZJ: IL-37 induces autophagy in hepatocellular carcinoma cells by inhibiting the PI3K/AKT/mTOR pathway. Mol Immunol 87: 132-140, 2017.
39. Wang SS, Chen YH, Chen N, Wang LJ, Chen DX, Weng HL, Dooley S and Ding HG: Hydrogen sulfide promotes autophagy of hepatocellular carcinoma cells through the PI3K/Akt/mTOR signaling pathway. Cell Death Dis 8: e2688, 2017.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.